Syndax Pharmaceuticals, Inc. (SNDX) Stock Price

SNDXStock

$12.90−14.29%52W

Market Cap$1.14B

P/E—

PEG Ratio—

Div yield—

Beta0.42

SNDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-57.10%

Price vs S&P 500 (4W)-27.29%

VGM Score49.51

Book Value / Share (Quarterly)$0.17

P/TBV (Annual)2.31x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-44.66%

Cash Flow / Share (Quarterly)$-2.48

Price vs S&P 500 (YTD)-50.53%

Gross Margin (TTM)95.78%

Net Profit Margin (TTM)-87.52%

EPS (TTM)$-2.52

10-Day Avg Trading Volume2.51M

EPS Excl Extra (TTM)$-2.52

Revenue Growth (5Y)158.26%

EPS (Annual)$-3.29

ROI (Annual)-69.86%

Gross Margin (Annual)95.96%

Net Profit Margin (5Y Avg)-2021.44%

Cash / Share (Quarterly)$6.22

Revenue Growth QoQ (YoY)91.76%

ROA (Last FY)-53.88%

Revenue Growth TTM (YoY)222.65%

EBITD / Share (TTM)$-2.21

ROE (5Y Avg)-123.17%

Operating Margin (TTM)-76.98%

Cash Flow / Share (Annual)$-3.70

P/B Ratio76.29x

P/B Ratio (Quarterly)128.29x

Net Income / Employee (Annual)$-957,800

EV / Revenue (TTM)5.56x

Net Interest Coverage (TTM)-24.82x

ROA (TTM)-39.11%

EV / EBITDA (TTM)1242.10x

EPS Incl Extra (Annual)$-3.29

Current Ratio (Annual)4.40x

Quick Ratio (Quarterly)6.32x

3-Month Avg Trading Volume1.82M

52-Week Price Return-14.29%

Revenue / Employee (TTM)$846,500

Tangible BV / Share (Quarterly)$5.16

P/S Ratio (Annual)6.68x

Asset Turnover (Annual)0.33x

52-Week High$25.59

Operating Margin (5Y Avg)-2033.49%

EPS Excl Extra (Annual)$-3.29

Tangible BV CAGR (5Y)34.98%

26-Week Price Return-47.20%

Quick Ratio (Annual)4.04x

13-Week Price Return-43.42%

Total Debt / Equity (Annual)5.32x

Current Ratio (Quarterly)6.77x

Enterprise Value$1.40B

Revenue / Share Growth (5Y)122.73%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-32.47%

Revenue / Employee (Annual)$578,400

Pretax Margin (Annual)-165.60%

Cash / Share (Annual)$4.73

3-Month Return Std Dev49.36%

Net Income / Employee (TTM)$-740,800

ROE (Last FY)-441.62%

Net Interest Coverage (Annual)-7.66x

EPS Basic Excl Extra (Annual)$-3.29

Receivables Turnover (TTM)7.82x

Total Debt / Equity (Quarterly)38.95x

EPS Incl Extra (TTM)$-2.52

ROI (TTM)-47.56%

P/S Ratio (TTM)4.57x

Pretax Margin (5Y Avg)-2021.44%

Revenue / Share (Annual)$1.99

Tangible BV / Share (Annual)$6.86

Price vs S&P 500 (52W)-29.82%

Year-to-Date Return-38.60%

5-Day Price Return-22.05%

EPS Normalized (Annual)$-3.29

ROA (5Y Avg)-31.30%

Net Profit Margin (Annual)-165.60%

Month-to-Date Return-31.38%

Cash Flow / Share (TTM)$-2.59

EBITD / Share (Annual)$-3.15

Operating Margin (Annual)-158.45%

LT Debt / Equity (Annual)5.32x

ROI (5Y Avg)-36.84%

LT Debt / Equity (Quarterly)38.95x

EPS Basic Excl Extra (TTM)$-2.52

P/TBV (Quarterly)3.01x

P/B Ratio (Annual)28.25x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-87.52%

Book Value / Share (Annual)$0.74

Price vs S&P 500 (13W)-46.11%

Beta0.42x

P/FCF (Annual)39.72x

Revenue / Share (TTM)$2.83

ROE (TTM)-372.94%

52-Week Low$12.81

vGradeD

gGradeA

mGradeD

vgmGradeC

SNDX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.44	-$0.55	-26.01%(-$0.11)
Q1 2026	Apr 30, 2026	-$0.59	-$0.48	+18.76%(+$0.11)
Q4 2025	Feb 26, 2026	-$0.58	-$0.78	-34.89%(-$0.20)
Q3 2025	Nov 3, 2025	-$0.71	-$0.70	+1.54%(+$0.01)
Q2 2025	Aug 4, 2025	-$1.01	-$0.83	+17.50%(+$0.18)

SNDX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.35

4.37

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SNDXSyndax Pharmaceuticals, Inc.	D	A	D	4.6x	222.7%	95.8%	—	$12.90
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer and immune-related diseases. Its pipeline includes revumenib, a selective menin-MLL inhibitor for acute leukemias; axatilimab, a CSF-1R antibody for chronic graft-versus-host disease and pulmonary fibrosis; and entinostat, an oral small molecule targeting cancer cells and immune cells. The company is based in the United States.

SNDX Next Earnings Report

Report dateNov 2, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.49

Revenue estimate$81.92M

Also reporting on Nov 2, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

INBXInhibrx Biosciences, Inc. Common StockBiological Products
EPCEdgewell Personal Care CompanyCosmetics & Toiletries
CRONCronos Group Inc. Common SharePharmaceutical Preparations
TSHATaysha Gene Therapies, Inc. Common StockBiological Products
ECVTEcovyst Inc.Chemicals
ODDODDITY Tech Ltd. Class A Ordinary SharesCosmetics & Toiletries
IMTXImmatics N.V. Ordinary SharesBiological Products
REPLReplimune Group, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.4

Strong Buy

Consensus rating

52-Week Range

Low$12.81

High$25.59